Program

The 13th International HBV Cure Workshop 2026 will be held in Denver, Colorado on November 4, 2026, right before The Liver Meeting® (TLM) 2026 by AASLD. This highly anticipated workshop brings together global inter-disciplinary experts to provide a framework for how academia and industry should collaborate to achieve the goal of curing hepatitis B.

Since its inception in 2014, the International HBV Cure Workshop has been a pivotal scientific platform aimed at accelerating the progress towards finding a cure for HBV.

The HBV treatment landscape is experiencing significant transformations and is on the brink of a paradigm shift. The emergence of numerous new treatment options brings great hope for reducing the disease burden, simplifying treatment protocols, and potentially curing and eradicating HBV infection. To optimize curative treatments for HBV, distinguished speakers from around the world will present the latest therapeutic options.

Wednesday, November 4, 2026
8:30 AM - 8:40 AM																WORKSHOP OPENING
8:40 AM - 10:10 AM																SESSION I 08:40 – 09:00 Baseline HBsAg levels in HBsAg loss, functional cure and setpoint after therapy discontinuation 09:00 – 09:20 Partial cure and long-term outcomes: what data do we need? 09:20 – 09:40 Antisense oligonucleotides as the backbone for new combination therapies 09:40 – 10:10 Discussion
10:10 AM - 10:30 AM																AM BREAK
10:30 AM - 12:00 PM																SESSION II 10:30 – 10:50 How much would effective immunotherapy impact functional cure rates? 10:50 – 11:10 Clinical perspective of managing novel HBV combination therapies: efficacy vs. AEs & Complexity 11:10 – 11:30 How much are patients willing to accept to achieve durable functional cure? 11:30 – 12:00 Discussion
12:00 PM - 1:00 PM																LUNCH BREAK
1:00 PM - 2:40 PM																SESSION III - IMMUNOLOGY 13:00 – 13:20 Cell-free DNA in disease progression and therapeutic response: opportunities for host-specific biomarkers 13:20 – 13:30 GS-2829 + GS-6779 vaccine 13:30 – 13:40 VRON-0200 14:00 – 14:40 Discussion
2:40 PM - 3:10 PM																PM BREAK
3:10 PM - 5:00 PM																SESSION IV - ANTIVIRALS 15:10 – 15:30 Spatial distribution of integrated vs infected hepatocytes in the human liver 15:30 – 15:40 Bepi + siRNA 15:40 – 15:50 AHB-137 15:50 – 16:00 Pevifoscovir 16:00 – 16:10 Tune-401 16:10 – 16:25 PBGENE-HBV 16:25 – 16:55 Delta Roundtable Discussion: Is HDV curable in the majority of patients? 16:55 – 17:00 Closing Remarks
4:55 PM - 5:00 PM																CLOSING REMARKS
5:00 PM - 6:30 PM																The Forum for Collaborative Research-HBV Forum 17
6:30 PM - 8:30 PM																NETWORKING RECEPTION